N4 Pharma AI Stock Analysis
Want to see GB:THAT full AI Analyst Report?
N4 Pharma (THAT) AI Stock Analysis
N4 Pharma
(LSE:THAT)
The overall score is at the minimum of 37, driven by uniformly weak fundamentals and technicals. The company's financial position is fragile with significant cash burn and no clear path to profitability. This is compounded by a bearish technical picture with the stock trading below all major moving averages and deeply oversold conditions. The lack of positive valuation metrics or corporate catalysts offers no offsetting support.
N4 Pharma (THAT) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 4.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 904.38K
- Price to Earnings (P/E)
- -7.2
- Beta (1Y)
- 1.32
- Revenue Growth
- 2.12%
- EPS Growth
- 29.17%
- Country
- UK
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
N4 Pharma Business Overview & Revenue Model
Company Description
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular...
How the Company Makes Money
N4 Pharma is an R&D-stage drug delivery company; specific, consistently recurring commercial revenue streams are not publicly evidenced in the information available to me here, so a definitive breakdown of how it currently makes money cannot be state...
N4 Pharma Financial Statement Overview
Summary
Financial performance is very weak, typical of a pre-revenue biotech. Negligible revenue, persistent operating losses, negative cash flows, and a thin equity base relative to the cash burn rate result in a score at the bottom of the range.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7,216 | 7,264 | 7,282 | 1,953 | 0 | 0 |
| Gross Profit | 0 | 7,264 | 7,282 | 1,953 | 0 | 0 |
| EBITDA | -1.39M | -1.10M | -1.22M | -1.33M | -1.19M | -1.84M |
| Net Income | -1.46M | -1.21M | -1.06M | -1.27M | -1.03M | -1.54M |
Balance Sheet | ||||||
| Total Assets | 2.71M | 1.17M | 775.77K | 1.28M | 2.17M | 2.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.50M | 1.08M | 625.97K | 1.03M | 1.92M | 1.78M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 245.66K | 97.96K | 124.37K | 81.73K | 77.89K | 212.73K |
| Stockholders Equity | 2.46M | 1.07M | 647.65K | 1.13M | 2.09M | 2.13M |
Cash Flow | ||||||
| Free Cash Flow | -1.46M | -1.16M | -971.50K | -1.21M | -828.26K | -1.77M |
| Operating Cash Flow | -1.46M | -1.16M | -971.50K | -1.21M | -828.26K | -1.77M |
| Investing Cash Flow | 0 | 0 | 0 | 781 | 0 | 0 |
| Financing Cash Flow | 1.24M | 1.61M | 570.36K | 315.90K | 963.77K | 677 |
N4 Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:THAT, the sentiment is Neutral. The current price of 0.57 is below the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.59, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.88 is Neutral, neither overbought nor oversold. The STOCH value of 78.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:THAT.
N4 Pharma Peers Comparison
Overall Rating
GB:EAH61Neutral
GB:PXS44Neutral
GB:STX43Neutral
GB:CHLL38Underperform
GB:THAT37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | GBP 56.24M | 25.70 | 2.55% | ― | 9.96% | 29.72% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | GBP 16.54M | -70.50 | -44.68% | ― | -2.14% | 0.00% | |
| 43Neutral | GBP 32.76M | -4.08 | 64.57% | ― | 36.19% | 60.75% | |
| 38Underperform | GBP 836.68K | -0.00 | 233.76% | ― | ― | ― | |
| 37Underperform | GBP 14.18M | -7.19 | -82.76% | ― | 2.12% | 29.17% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:THAT | N4 Pharma | 0.57 | 0.00 | 0.00% | |
| GB:EAH | Eco Animal Health | 83.00 | -9.00 | -9.78% | |
| GB:CHLL | Chill Brands Group PLC | 1.55 | -8.20 | -84.10% | |
| GB:HELD | Mountfield Group plc | 0.90 | -0.05 | -5.26% | |
| GB:PXS | Provexis plc | 0.68 | 0.11 | 18.26% | |
| GB:STX | Shield Therapeutics | 3.05 | -4.65 | -60.39% |
N4 Pharma Corporate Events
Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline
PositiveThalia Therapeutics reported interim results marking its strategic transformation from a delivery-platform business into a diversified, clinical-stage RNA therapeutics company in oncology and cardiovascular disease. The appointment of CEO Dr David So...
Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten
PositiveThalia Therapeutics has secured a new patent in China for its lead acute myeloid leukaemia drug candidate miRisten, extending protection for the RNA-based therapy in a major oncology market. The patent builds on existing rights licensed from City of...
Thalia Therapeutics Advances Dual-Target RNA Cardiovascular Drug THAT-002
PositiveThalia Therapeutics has completed initial chemistry synthesis for THAT-002, a bispecific siRNA gene-silencing therapy targeting PCSK9 and lipoprotein(a) to lower cardiovascular disease risk. The programme, developed with WuXi AppTec, marks a key earl...
Thalia Therapeutics Advances RNA Portfolio After Strategic Transformation
PositiveThalia Therapeutics has completed its transition into a clinical-stage RNA therapeutics business after rebranding from N4 Pharma and acquiring Sanmirna Therapeutics, and will report interim results for the six months to 30 June 2026 on 30 September....
Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances
PositiveThalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based therapies for cancer and cardiovascular conditions, is advancing a differentiated pipeline anchored by validated genetic targets and proprietary delivery technolo...
Thalia Therapeutics Grants Major Director Option Package Tied to Share Price Targets
NeutralThalia Therapeutics has granted options over 200,000,000 ordinary shares to five directors under its share option plan, following its recent AGM and the completion of the acquisition of Sanmirna Therapeutics. The board says the ten-year options, pric...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026
